

# HERO-TOGETHER: Highlights from an interim report

**HERO**  
**TOGETHER**  
KEEPING COMMUNITIES  
HEALTHY WITH VACCINATION



## THANK YOU, PARTICIPANTS!

The HERO Research team is pleased to share with you interim results from HERO-TOGETHER, a post-COVID-19 vaccine observational study. These results were submitted to the U.S. Food and Drug Administration (FDA) and includes data collected during the first six months, December 2020 to June.



### WHY IS THIS RESEARCH IMPORTANT?

Data and experiences from participants in clinical trials who received a COVID-19 vaccine was used by drug companies when seeking Emergency

Use Authorization (EUA) of the vaccines by the FDA. After EUA authorization, continuing to collect experiences after vaccination will help us understand the long-term health effects and efficacy of COVID-19 vaccines.



### WHERE ARE PARTICIPANTS FROM?

HERO-TOGETHER participants represent all 50 states plus the District of Columbia.



### ABOUT THE HERO REGISTRY

HERO-TOGETHER is one of the research opportunities available through the Healthcare Worker Exposure Response & Outcomes (HERO)

Registry. The Registry is a community of people who share what it is like to work and live during the COVID-19 pandemic. The HERO Registry is open to healthcare workers, their families, and community members.



### STAY CONNECTED:

Visit: [heroesresearch.org/together](https://heroesresearch.org/together)  
Follow us on social @HeroesResearch



### WHO IS INVOLVED?

This first report included data from **7,824** people who received the first dose of a COVID-19 vaccine within **60 days** of joining the study.

MEAN AGE  
**43 years**

PREGNANT AT TIME  
OF FIRST DOSE  
**3%**

FEMALE  
**66%**

WHITE OR CAUCASIAN  
**72%**

HISPANIC OR LATINO  
**5%**

### TOP 5 HEALTHCARE WORKER ROLES



1. Registered Nurse
2. Physician
3. Resident/Fellow
4. Physician Assistant
5. Nurse Practitioner



### WHAT'S NEXT?

HERO-TOGETHER participants will continue to share their experiences for up to 2 years after receiving the vaccine. The team will continue to provide interim reports of additional study data to the FDA.

Once all study data is collected, the HERO Research team will analyze the information and share results with participants, HERO Registry members, regulatory agencies, the scientific community, and the public.

*The HERO Registry is funded through a Patient-Centered Outcomes Research Institute Award. The program is coordinated by the Duke Clinical Research Institute and leverages PCORnet®, the National Patient-Centered Clinical Research Network.*

*Funding for the HERO-TOGETHER study is provided by Pfizer, including the online platform operated by a company called Verily. All study activities are overseen by the Duke Clinical Research Institute*